Startup Name: Cogentis Therapeutics

Startup Category: Health Care



Description: Cogentis Therapeutics is a pre-clinical stage biotechnology company developing and de-risking first-in-class curative therapies for Alzheimer’s disease (AD) and related neurodegenerative disorders such as frontotemporal dementia (FTD). With strong preclinical data from multiple laboratories, we are in collaboration with researchers at the NIH, Harvard, MIT and Johns Hopkins to further develop and clinically validate our lead asset, CT-526, which modulates a well-studied and tractable dysfunctional brain enzyme target, CDK5, that can cause dementia. There are currently no approved drugs that modify or halt the progression of any dementia disorder and we intend to be the first to offer a much needed therapy within an untapped multi-billion dollar market - ultimately via partnership with a major Pharma company.

Contact Person: Ryan Spangler | Phone Number: 443-605-4885 | Email:

Association: Johns Hopkins University/Medical